Treatment of NPCs using rapamycin, the only FDA approved treatment for TSC patients to date, led to a partial reversal in TSC1-associated translation, yet most genes related to neural activity/synaptic regulation or ASD remained unchanged. This evidence concerns the gene TSC1 and tuberous sclerosis.